The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy.
Ontology highlight
ABSTRACT: To assess the potential clinical utility of cell-free DNA (cfDNA)-based biomarkers for identifying gastric cancer (GC) patients who benefit from nivolumab. From 31 GC patients treated with nivolumab monotherapy (240 mg/body, Bi-weekly) in 3rd or later line setting, we prospectively collected blood samples at baseline and before the 3rd dose. We compared cfDNA-based molecular findings, including microsatellite instability (MSI) status, to tissue-based biomarkers. We assessed the clinical value of blood tumor mutation burden (bTMB) and copy number alterations (CNA) as well as the cfDNA dynamics. The concordance between deficient-MMR and cfDNA-based MSI-high was 100% (3/3). Patients with bTMB ≥ 6 mut/Mb had significantly better progression-free survival (PFS) and overall survival (OS); howeve
SUBMITTER: Inagaki C
PROVIDER: S-EPMC10079661 | biostudies-literature | 2023 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA